Eli Lilly has won U.K. approval for its weight-loss pill Foundayo, its first authorisation beyond the U.S. market, taking its competition with Novo Nordisk's Wegovy global, according to CNBC.
Key facts
- Eli Lilly's weight-loss pill Foundayo won U.K. approval, CNBC reported.
- The approval is Foundayo's first outside the U.S. market, according to CNBC.
- CNBC said the move takes Lilly's rivalry with Novo Nordisk's Wegovy beyond the U.S.
- The development was reported by CNBC on 11 August 2026.
Eli Lilly has secured U.K. approval for its weight-loss pill Foundayo, according to CNBC. The decision marks the drug’s first authorisation outside the United States.
The approval takes Lilly’s weight-loss pill battle with Novo Nordisk’s Wegovy beyond the U.S. market, CNBC reported.
Further details about the approval, including timing of availability and regulatory conditions, were not specified in the reporting available.
Why it matters
CNBC reported that the U.K. approval marks Foundayo's first authorisation outside the United States, extending Lilly's competition with Novo Nordisk's Wegovy into a new market.
Frequently asked questions
What is Foundayo?
Foundayo is Eli Lilly's weight-loss pill, which has now won approval in the U.K., according to CNBC.
Why is the U.K. approval significant?
It is Foundayo's first approval outside the U.S. market, taking Lilly's competition with Novo Nordisk's Wegovy beyond the United States, CNBC reported.
Which competitor is Lilly facing?
Lilly is competing with Novo Nordisk's Wegovy in the weight-loss treatment market.